PIONEER 1: randomized clinical trial comparing the efficacy and safety of oral semaglutide monotherapy with placebo in patients with type 2 diabetes
It is important to understand that Mounjaro is not suitable for everyone, and it must only be used following a full clinical assessment
BPC-157 (Body Protection Compound-157) is a synthetic peptide that has garnered attention for its potential regenerative and healing properties
Blamire AM, Anthony DC, Rajagopalan B et al (2000) Interleukin-1-induced changes in blood-brain barrier permeability, apparent diffusion coefficient, and cerebral blood volume in the rat brain: a magnetic resonance study
Ivancovsky Wajcman D, Byrne CJ, Dillon JF, et al
Although there are many ongoing large CVD outcome trials of GLP-1 RA treatment (Table 1), more simultaneous investigation of the causal relationship between GLP-1 RA administration and useful surrogate measures of CVD, including carotid IMT, would help us understand the potential mechanisms through which GLP-1 RAs may result in favorable cardiovascular outcomes in patients with T2D